XML 88 R28.htm IDEA: XBRL DOCUMENT

Restructuring and Asset Impairment Charges (Tables)

6 Months Ended

Sep. 30, 2019

Restructuring and Related Activities [Abstract]

Restructuring, Impairment and Related Costs

Restructuring, impairment and related charges for our fiscal 2019 initiatives during the second quarter and first six months of 2020 consisted of the following:



	Quarter Ended September 30, 2019
(In millions)	U.S. Pharmaceutical and Specialty Solutions		European Pharmaceutical Solutions		Medical-Surgical Solutions		Other		Corporate		Total
Severance and employee-related costs, net	$	2	$	3	$	1	$	1	$	10	$	17
Exit and other-related costs ⁽¹⁾	—		4		2		—		13		19
Asset impairments and accelerated depreciation	—		3		—		—		4		7
Total	$	2	$	10	$	3	$	1	$	27	$	43



	Six Months Ended September 30, 2019
(In millions)	U.S. Pharmaceutical and Specialty Solutions		European Pharmaceutical Solutions		Medical-Surgical Solutions		Other		Corporate		Total
Severance and employee-related costs, net	$	1	$	2	$	1	$	1	$	16	$	21
Exit and other-related costs ⁽¹⁾	—		5		4		1		23		33
Asset impairments and accelerated depreciation	—		6		1		—		5		12
Total	$	1	$	13	$	6	$	2	$	44	$	66


(1)	Exit and other-related costs primarily include project consulting fees.

Restructuring, impairment and related charges for our fiscal 2019 initiatives during the second quarter and first six months of 2019 consisted of the following:



	Quarter Ended September 30, 2018
(In millions)	U.S. Pharmaceutical and Specialty Solutions		Medical-Surgical Solutions		Other		Corporate		Total
Severance and employee-related costs, net	$	—	$	—	$	6	$	4	$	10
Exit and other-related costs ⁽¹⁾	5		5		35		18		63
Asset impairments and accelerated depreciation	—		1		1		—		2
Total	$	5	$	6	$	42	$	22	$	75



	Six Months Ended September 30, 2018
(In millions)	U.S. Pharmaceutical and Specialty Solutions		Medical-Surgical Solutions		Other		Corporate		Total
Severance and employee-related costs, net	$	3	$	10	$	7	$	4	$	24
Exit and other-related costs ⁽¹⁾	6		7		56		29		98
Asset impairments and accelerated depreciation	4		1		17		—		22
Total	$	13	$	18	$	80	$	33	$	144

(1)

Exit and other-related costs primarily include lease exit costs associated with closures of retail pharmacy stores within our Canadian business as well as project consulting fees.

Schedule of Restructuring and Asset Impairment Charges

The following table summarizes the activity related to the restructuring liabilities associated with our fiscal 2019 initiatives for the first six months of 2020:



(In millions)	U.S. Pharmaceutical and Specialty Solutions			European Pharmaceutical Solutions			Medical-Surgical Solutions			Other			Corporate			Total
Balance, March 31, 2019 ⁽¹⁾	$	31		$	38		$	15		$	29		$	37		$	150
Restructuring, impairment and related charges	1			13			6			2			44			66
Non-cash charges	—			(6		)	(1		)	—			(5		)	(12		)
Cash payments	(3		)	(10		)	(1		)	(14		)	(22		)	(50		)
Other	—			(1		)	—			(7		)	(5		)	(13		)
Balance, September 30, 2019 ⁽²⁾	$	29		$	34		$	19		$	10		$	49		$	141


(1)	As of March 31, 2019, the total reserve balance was $150 million of which $117 million was recorded in other accrued liabilities and $33 million was recorded in other noncurrent liabilities.

(2)

As of September 30, 2019, the total reserve balance was $141 million of which $119 million was recorded in other accrued liabilities and $22 million was recorded in other noncurrent liabilities.